Soliris safety checked in korean patients
NCT ID NCT06448715
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective the drug Soliris is for Korean patients with a rare disease called NMOSD. It involved 11 people who were already taking the drug as part of their normal medical care. The goal was to track side effects and see if the drug helped prevent relapses in everyday practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Goyang-si, South Korea
-
Research Site
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases
- Experimental CAR t treatment targets root cause of rare nerve disease
- New hope for NMOSD patients: drug aims to slash relapse rate